keyword
MENU ▼
Read by QxMD icon Read
search

CoreValve evolut

keyword
https://www.readbyqxmd.com/read/28724752/the-fluid-mechanics-of-transcatheter-heart-valve-leaflet-thrombosis-in-the-neo-sinus
#1
Prem A Midha, Vrishank Raghav, Rahul Sharma, Jose F Condado, Ikechukwu U Okafor, Tanya Rami, Gautam Kumar, Vinod H Thourani, Hasan Jilaihawi, Vasilis Babaliaros, Raj R Makkar, Ajit P Yoganathan
Background -Transcatheter heart valve (THV) thrombosis has been increasingly reported. In these studies, thrombus quantification has been based on 2D assessment of a 3D phenomenon. Methods -Post-procedural four-dimensional, volume-rendered CT (4DCT) data of CoreValve, Evolut R, and SAPIEN 3 transcatheter aortic valve replacement (TAVR) patients enrolled in the RESOLVE trial were included in this analysis. Patients on anticoagulation were excluded. SAPIEN 3 and CoreValve/Evolut R patients with and without hypo-attenuated leaflet thickening (HALT) were included in order to study differences between groups...
July 19, 2017: Circulation
https://www.readbyqxmd.com/read/28616543/transcatheter-aortic-valve-implantation-with-the-new-generation-evolut-r%C3%A2-comparison-with-corevalve%C3%A2-in-a-single-center-cohort
#2
Eberhard Schulz, Alexander Jabs, Tommaso Gori, Stephan von Bardeleben, Ulrich Hink, Walter Kasper-König, Christian Friedrich Vahl, Thomas Münzel
BACKGROUND: The Medtronic Evolut R (EVR) is a novel transcatheter heart valve designed to allow precise implantation at the intended position and to minimize prosthesis dysfunction as well as procedural complications. Our aim was to compare short-term functional and clinical outcomes of the new EVR with the established Medtronic CoreValve (CV) system. METHODS AND RESULTS: Of 151 patients undergoing transfemoral transcatheter aortic valve implantation with a self-expanding valve at our institution between January 2013 and January 2016, 86 were treated with EVR and 65 with CV...
September 2016: IJC Heart & Vasculature
https://www.readbyqxmd.com/read/28595747/transcathether-aortic-valve-implantation-with-the-new-repositionable-self-expandable-evolut-r-versus-corevalve-system-a-case-matched-comparison
#3
Cristina Giannini, Marco De Carlo, Corrado Tamburino, Federica Ettori, Azeem M Latib, Francesco Bedogni, Giuseppe Bruschi, Patrizia Presbitero, Arnaldo Poli, Franco Fabbiocchi, Roberto Violini, Carlo Trani, Pietro Giudice, Marco Barbanti, Marianna Adamo, Paola Colombo, Susanna Benincasa, Mauro Agnifili, A Sonia Petronio
BACKGROUND: Despite promising results following transcatheter aortic valve implantation (TAVI), several relevant challenges still remain. To overcome these issues, new generation devices have been developed. The purpose of the present study was to determine whether TAVI with the new self-expanding repositionable Evolut R offers potential benefits compared to the preceding CoreValve, using propensity matching. METHODS: Between June 2007 and November 2015, 2148 consecutive patients undergoing TAVI either CoreValve (n=1846) or Evolut R (n=302) were prospectively included in the Italian TAVI ClinicalService® project...
May 29, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28535198/transcatheter-aortic-valve-implantation-for-recurrent-valsalva-sinus-re-dissection-and-severe-aortic-regurgitation-shortly-after-surgery-for-type-a-aortic-dissection
#4
Elena Caporali, Giovanni Pedrazzini, Stefanos Demertzis, Enrico Ferrari
Delayed aortic regurgitation following Valsalva sinus re-dissection is a well-known complication that can occur at any time after surgery for type-A aortic dissection without root replacement. We describe a case of acute type-A dissection in an 81-year-old lady successfully treated with aortic valve resuspension and ascending aorta replacement with a 28-mm vascular graft. A month later, the patient was readmitted for worsening heart failure and a transthoracic echocardiogram showed severe aortic regurgitation secondary to non-coronary Valsalva sinus re-dissection and non-coronary aortic valve leaflet prolapse also confirmed at computed tomography scan...
May 23, 2017: Interactive Cardiovascular and Thoracic Surgery
https://www.readbyqxmd.com/read/28513189/transcatheter-aortic-valve-implantation-the-transaortic-approach
#5
Simon Cy Chow, Gary Sh Cheung, Alex Pw Lee, Eugene B Wu, Jacky Yk Ho, Micky Wt Kwok, Peter Sy Yu, Innes Yp Wan, Malcolm J Underwood, Randolph Hl Wong
Background Transcatheter aortic valve implantation has been established as a safe and effective treatment option for patients at high or prohibitive surgical risk. However, some patients may not be suitable for the transfemoral approach due to severe iliofemoral disease or aneurysmal disease of the thoracoabdominal aorta. The aim of this case series was to evaluate the feasibility and clinical outcomes of the transaortic approach. Methods From May 2015 to June 2016, 5 patients (mean age 78.4 ± 3.9 years) with severe symptomatic aortic stenosis underwent transaortic transcatheter aortic valve implantation after a heart team discussion...
January 1, 2017: Asian Cardiovascular & Thoracic Annals
https://www.readbyqxmd.com/read/28493389/contemporary-transcatheter-aortic-valve-replacement-with-third-generation-balloon-expandable-versus-self-expanding-devices
#6
Toby Rogers, Arie Steinvil, Kyle Buchanan, M Chadi Alraies, Edward Koifman, Jiaxiang Gai, Rebecca Torguson, Petros Okubagzi, Itsik Ben-Dor, Augusto Pichard, Lowell Satler, Ron Waksman
OBJECTIVES: To evaluate balloon-expandable and self-expanding third-generation transcatheter aortic valve replacement (TAVR) devices according to patient selection criteria and outcomes. BACKGROUND: Two competing third-generation TAVR technologies are currently commercially available in the US. There are no published head-to-head comparisons of the relative performance of these two devices. METHODS: 257 consecutive patients undergoing TAVR with a third-generation balloon-expandable (Edwards Sapien 3) or self-expanding device (Medtronic CoreValve Evolut R) at a single US medical center were included...
May 11, 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/28330793/outcomes-in-transcatheter-aortic-valve-replacement-for-bicuspid-versus-tricuspid%C3%A2-aortic%C3%A2-valve-stenosis
#7
Sung-Han Yoon, Sabine Bleiziffer, Ole De Backer, Victoria Delgado, Takahide Arai, Johannes Ziegelmueller, Marco Barbanti, Rahul Sharma, Gidon Y Perlman, Omar K Khalique, Erik W Holy, Smriti Saraf, Florian Deuschl, Buntaro Fujita, Philipp Ruile, Franz-Josef Neumann, Gregor Pache, Masao Takahashi, Hidehiro Kaneko, Tobias Schmidt, Yohei Ohno, Niklas Schofer, William K F Kong, Edgar Tay, Daisuke Sugiyama, Hiroyuki Kawamori, Yoshio Maeno, Yigal Abramowitz, Tarun Chakravarty, Mamoo Nakamura, Shingo Kuwata, Gerald Yong, Hsien-Li Kao, Michael Lee, Hyo-Soo Kim, Thomas Modine, S Chiu Wong, Francesco Bedgoni, Luca Testa, Emmanuel Teiger, Christian Butter, Stephan M Ensminger, Ulrich Schaefer, Danny Dvir, Philipp Blanke, Jonathon Leipsic, Fabian Nietlispach, Mohamed Abdel-Wahab, Bernard Chevalier, Corrado Tamburino, David Hildick-Smith, Brian K Whisenant, Seung-Jung Park, Antonio Colombo, Azeem Latib, Susheel K Kodali, Jeroen J Bax, Lars Søndergaard, John G Webb, Thierry Lefèvre, Martin B Leon, Raj Makkar
BACKGROUND: Transcatheter aortic valve replacement (TAVR) is being increasingly performed in patients with bicuspid aortic valve stenosis (AS). OBJECTIVES: This study sought to compare the procedural and clinical outcomes in patients with bicuspid versus tricuspid AS from the Bicuspid AS TAVR multicenter registry. METHODS: Outcomes of 561 patients with bicuspid AS and 4,546 patients with tricuspid AS were compared after propensity score matching, assembling 546 pairs of patients with similar baseline characteristics...
May 30, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28283233/effect-of-transcatheter-aortic-valve-size-and-position-on-valve-in-valve-hemodynamics-an-in%C3%A2-vitro-study
#8
Ali N Azadani, Michael Reardon, Matheus Simonato, Gabriel Aldea, Georg Nickenig, Ran Kornowski, Danny Dvir
OBJECTIVE: Transcatheter heart valve implantation in failed aortic bioprostheses (valve-in-valve [ViV]) is an increasingly used therapeutic option for high-risk patients. However, high postprocedural gradients are a significant limitation of aortic ViV. Our objective was to evaluate Medtronic CoreValve Evolut R ViV hemodynamics in relation to the degree of device oversizing and depth of implantation. METHODS: Evolut R devices of 23 and 26 mm were implanted within 21-, 23-, and 25-mm Hancock II bioprostheses...
February 10, 2017: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/28183466/early-clinical-outcomes-after-transcatheter%C3%A2-aortic-valve-replacement-using-a-novel-self-expanding-bioprosthesis%C3%A2-in%C3%A2-patients-with-severe%C3%A2-aortic%C3%A2-stenosis-who-are-suboptimal%C3%A2-for%C3%A2-surgery-results-of-the-evolut-r-u-s-study
#9
Jeffrey J Popma, Michael J Reardon, Kamal Khabbaz, J Kevin Harrison, G Chad Hughes, Susheel Kodali, Isaac George, G Michael Deeb, Stan Chetcuti, Robert Kipperman, John Brown, Hongyan Qiao, James Slater, Mathew R Williams
OBJECTIVES: This study sought to evaluate this transcatheter aortic valve (TAV) bioprosthesis in patients who are poorly suitable for surgical aortic valve (AV) replacement. BACKGROUND: A novel self-expandable TAV bioprosthesis was designed to provide a low-profile delivery system, conformable annular sealing, and the ability to resheath and reposition during deployment. METHODS: The Evolut R U.S. study included 241 patients with severe aortic stenosis who were deemed to be at least high risk for surgery treated at 23 clinical sites in the United States...
February 13, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28145874/comparative-matched-outcome-of-evolut-r-vs-corevalve-transcatheter-aortic-valve-implantation
#10
Uri Landes, Tamir Bental, Alon Barsheshet, Abid Assali, Hana Vaknin Assa, Amos Levi, Katia Orvin, Ran Kornowski
OBJECTIVES: The Evolut-R (Medtronic, Inc) is a transcatheter aortic valve implantation (TAVI) system that was built on the well-established foundation of Medtronic's CoreValve device platform. Although already in extensive clinical utilization, it is unknown if the Evolut-R improves TAVI outcomes. Herein, we compared TAVI outcomes of the Evolut-R and CoreValve devices. METHODS: A propensity score 1:1 matching was conducted on 358 Evolut-R patients (n = 75) and CoreValve patients (n = 283)...
February 2017: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/28067197/comparison-of-procedural-and-clinical-outcomes-with-evolut-r-versus-medtronic-corevalve-a-swiss-tavi-registry-analysis
#11
Stephane Noble, Stefan Stortecky, Dik Heg, David Tuller, Raban Jeger, Stefan Toggweiler, Enrico Ferrari, Fabian Nietlispach, Maurizio Taramasso, Francesco Maisano, Jürg Grünenfelder, Peter Jüni, Christoph Huber, Thierry Carrel, Stephan Windecker, Peter Wenaweser, Marco Roffi
AIMS: Data on procedural and clinical outcomes after transcatheter aortic valve implantation (TAVI) with the new generation self-expanding Medtronic Evolut-R prosthesis in comparison with its predecessor, the Medtronic CoreValve, are scarce. METHODS AND RESULTS: In a nationwide, prospective, multi-center cohort study outcomes of consecutive transfemoral TAVI patients treated with the new- generation Medtronic Evolut-R (September 2014 - February 2016) and the Medtronic CoreValve (February 2011 - February 2016) were investigated...
January 10, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28034684/thirty-day-outcome-following-corevalve-evolut-r-transcatheter-aortic-valve-implantation-an-all-comers-prospective-study
#12
Nils Perrin, Marco Roffi, Angela Frei, Anne-Lise Hachulla, Christoph Ellenberger, Hajo Müller, Mustafa Cikirikcioglu, Marc Licker, Stephane Noble
INTRODUCTION AND OBJECTIVES: There are scarce clinical outcomes data on the new generation recapturable and repositionable CoreValve Evolut R. METHODS: Data on all-comer patients undergoing transcatheter aortic valve implantation (TAVI) with the Evolut R for severe symptomatic aortic stenosis at a single center were prospectively collected between February 2015 and April 2016. Clinical endpoints were independently adjudicated according to the Valve Academic Research Consortium-2 criteria...
December 26, 2016: Revista Española de Cardiología
https://www.readbyqxmd.com/read/27970048/tct-672-outcomes-in-the-commercial-use-of-self-expanding-prostheses-in-transcatheter-aortic-valve-replacement-a-comparison-of-the-medtronic-corevalve-and-evolut-r-platforms-in-the-society-of-thoracic-surgeons-american-college-of-cardiology-transcatheter-valve
#13
Paul Sorajja, Susheel Kodali, Michael Reardon, Wilson Szeto, Stanley Chetcuti, James Hermiller, David Adams, Jeffrey Popma
No abstract text is available yet for this article.
November 1, 2016: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/27882613/improvements-of-procedural-results-with-a-new-generation-self-expanding-transfemoral-aortic-valve-prosthesis-in-comparison-to-the-old-generation-device
#14
Bruna Gomes, Nicolas A Geis, Emmanuel Chorianopoulos, Benjamin Meder, Florian Leuschner, Hugo A Katus, Raffi Bekeredjian
OBJECTIVES: In this study, we compare procedural results of our first Evolut R (Medtronic, Minneapolis, MN, USA) implantations with the last CoreValve implantations. Main endpoints include paravalvular regurgitation, major vascular complications, stroke, and pacemaker implantation. BACKGROUND: The evolution of transcatheter aortic valve replacement (TAVR) was possible due to various technical improvements, leading to better periprocedural and long-term outcome. The newly designed Evolut R valve has the potential to further improve TAVR's performance...
February 2017: Journal of Interventional Cardiology
https://www.readbyqxmd.com/read/27847071/evolut-r-implantation-to-treat-severe-pure-aortic-regurgitation-in-a-patient-with-mitral-bioprosthesis
#15
Giuseppe Bruschi, Paola Colombo, Stefano Nava, Francesco Musca, Bruno Merlanti, Oriana Belli, Francesco Soriano, Luca Botta, Danile De Caria, Cristina Giannattasio, Claudio F Russo
Transcatheter aortic valves have been designed to treat high-risk surgical candidates affected by severe aortic stenosis, but little is known about the use of transcatheter valves in patients with severe pure aortic regurgitation. We describe the implantation of Medtronic CoreValve Evolut R (Medtronic, Minneapolis, MN) to treat an 82-year-old patient affected by severe pure aortic regurgitation who underwent prior mitral valve replacement with a biological valve protruding into the left ventricular outflow tract...
December 2016: Annals of Thoracic Surgery
https://www.readbyqxmd.com/read/27845874/initial-single-center-experience-with-the-fully-repositionable-transfemoral-lotus-aortic-valve-system
#16
Kai-Uwe Jarr, Florian Leuschner, Benjamin Meder, Hugo A Katus, Raffi Bekeredjian, Emmanuel Chorianopoulos
BACKGROUND: Transcatheter aortic valve replacement (TAVR) has become the standard therapy for patients with severe symptomatic aortic stenosis and unacceptable high risk for surgical aortic valve replacement. Several different devices for TAVR have been introduced so far, each of them with unique features. AIMS: To analyze our first real-world experience with the second- generation, mechanically expanded, fully repositionable transfemoral Lotus TAVR device (Boston Scientific)...
January 2017: Journal of Invasive Cardiology
https://www.readbyqxmd.com/read/27751324/tavi-for-aortic-regurgitation-india-s-first-case-with-corevalve-evolut-r
#17
A B Gopalamurugan, K Murali, B Jyotsana, A Jacob, V V Bashi
Transcatheter Aortic Valve Implantation (TAVI) is a well-described treatment for symptomatic calcific severe aortic stenosis. However, TAVI technology is being increasingly used around the world to treat selected cases of severe aortic regurgitation (AR). One of the main limitations of using TAVI technology for AR is the lack of calcification, which is common in such cases. This makes anchoring of a TAVI prosthesis to the aortic annulus difficult and risks displacement or embolization. However, with the availability of recapturable and repositionable TAVI technologies, these limitations have been overcome to a large extent...
September 2016: Indian Heart Journal
https://www.readbyqxmd.com/read/27639744/in-vitro-evaluation-of-implantation-depth-in-valve-in-valve-using-different-transcatheter-heart-valves
#18
Matheus Simonato, Ali N Azadani, John Webb, Jonathon Leipsic, Ran Kornowski, Alec Vahanian, David Wood, Nicolo Piazza, Susheel Kodali, Jian Ye, Brian Whisenant, Diego Gaia, Mina Aziz, Tilak Pasala, Julinda Mehilli, Harindra C Wijeysundera, Didier Tchetche, Neil Moat, Rui Teles, Anna Sonia Petronio, David Hildick-Smith, Uri Landes, Stephan Windecker, Yaron Arbel, Oscar Mendiz, Raj Makkar, Elaine Tseng, Danny Dvir
AIMS: Transcatheter heart valve (THV) implantation in failed bioprosthetic valves (valve-in-valve [ViV]) offers an alternative therapy for high-risk patients. Elevated post-procedural gradients are a significant limitation of aortic ViV. Our objective was to assess the relationship between depth of implantation and haemodynamics. METHODS AND RESULTS: Commercially available THVs used for ViV were included in the analysis (CoreValve Evolut, SAPIEN XT and the Portico valve)...
September 18, 2016: EuroIntervention
https://www.readbyqxmd.com/read/27600519/transcatheter-aortic-valve-replacement-in-lower-surgical-risk-patients-review-of-major-trials-and-future-perspectives
#19
REVIEW
Mike Saji, D Scott Lim
Following the first successful transcatheter aortic valve replacement (TAVR) in 2002, TAVR has globally evolved to become a standard procedure in high-risk patients. Surgical aortic valve replacement in non-high-risk patients remains the gold standard for treatment of severe aortic stenosis. However, a paradigm shift appears to be occurring in the direction of treating lower-risk patients, and several studies have suggested its impact on clinical outcomes. In this review, we highlight the current status of TAVR in intermediate-risk patients and review major trials including Placement of AoRTic TraNscathetER (PARTNER) 2A randomized intermediate-risk trial using SAPIEN XT (Edwards Lifesciences Corp, Irvine, CA) recently presented with excellent outcomes and the lowest major complications rate at the American College of Cardiology's 65th Annual Scientific Session in Chicago...
October 2016: Current Cardiology Reports
https://www.readbyqxmd.com/read/27578840/outcomes-of-redo-transcatheter-aortic-valve-replacement-for-the-treatment-of-postprocedural-and-late-occurrence-of-paravalvular-regurgitation-and-transcatheter-valve-failure
#20
Marco Barbanti, John G Webb, Claudia Tamburino, Nicolas M Van Mieghem, Raj R Makkar, Nicolò Piazza, Azeem Latib, Jan-Malte Sinning, Kim Won-Keun, Sabine Bleiziffer, Francesco Bedogni, Samir Kapadia, Didier Tchetche, Josep Rodés-Cabau, Claudia Fiorina, Luis Nombela-Franco, Federico De Marco, Peter P de Jaegere, Tarun Chakravarty, Beatriz Vaquerizo, Antonio Colombo, Lars Svensson, Rüdiger Lange, Georg Nickenig, Helge Möllmann, Thomas Walther, Francesco Della Rosa, Yacine Elhmidi, Danny Dvir, Nedy Brambilla, Sebastiano Immè, Carmelo Sgroi, Simona Gulino, Denise Todaro, Gerlando Pilato, Anna Sonia Petronio, Corrado Tamburino
BACKGROUND: Transcatheter aortic valves can degenerate in a manner similar to surgical bioprostheses. METHODS AND RESULTS: Clinical and echocardiographic outcomes of patients who underwent redo transcatheter aortic valve replacement (TAVR) procedures >2 weeks post procedure were collected from 14 centers. Among 13 876 patients, 50 (0.4%) underwent redo TAVR procedure at participating centers. Indications for redo TAVR were moderate-severe prosthetic aortic valve stenosis (n=10, 21...
September 2016: Circulation. Cardiovascular Interventions
keyword
keyword
49670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"